Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic.
作者信息
Qing Guang-Chao, Zhang Hong, Bai Yang, Luo Yang
机构信息
Center of Smart Laboratory and Molecular Medicine, Medical School of Chongqing University, Chongqing, 400044, China.
Key Laboratory of Biorheological Science and Technology of Ministry of Education, School of Bioengineering, Chongqing University, Chongqing, 400044, China.
出版信息
Chin J Integr Med. 2020 Jun;26(6):403-404. doi: 10.1007/s11655-020-3095-6. Epub 2020 May 2.
Abstract
摘要
相似文献
1
Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic.中西医携手抗击新冠疫情。
Chin J Integr Med. 2020 Jun;26(6):403-404. doi: 10.1007/s11655-020-3095-6. Epub 2020 May 2.
2
Databases for facilitating mechanistic investigations of traditional Chinese medicines against COVID-19.促进中药抗COVID-19机制研究的数据库
Pharmacol Res. 2020 Sep;159:104989. doi: 10.1016/j.phrs.2020.104989. Epub 2020 Jun 2.
3
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Mar 11;16(685):510-511.
4
Importance of Environmental Factors on Production of Computationally- Defined Natural Molecules against COVID-19 Pandemic.环境因素对针对新冠疫情生成计算定义的天然分子的重要性。
Curr Top Med Chem. 2020;20(22):1958-1961. doi: 10.2174/156802662022200917110430.
5
A Call for a Three-Tiered Pandemic Public Health Strategy in Context of SARS-CoV-2.呼吁在新冠病毒背景下制定三级大流行公共卫生战略。
Rejuvenation Res. 2020 Aug;23(4):281-283. doi: 10.1089/rej.2020.2363. Epub 2020 Jun 24.
6
East meets West in COVID-19 therapeutics.在新冠病毒治疗中，东西方相遇了。
Pharmacol Res. 2020 Sep;159:105008. doi: 10.1016/j.phrs.2020.105008. Epub 2020 Jun 9.
7
Global research trends at the intersection of coronavirus disease 2019 (COVID-19) and traditional, integrative, and complementary and alternative medicine: a bibliometric analysis.全球研究趋势交汇于 2019 年冠状病毒病（COVID-19）与传统、整体、补充和替代医学：文献计量分析。
BMC Complement Med Ther. 2020 Nov 23;20(1):353. doi: 10.1186/s12906-020-03151-8.
8
Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.在新冠疫情期间，类似新冠病毒感染的检查点抑制剂肺炎。
Lung Cancer. 2020 Aug;146:376-377. doi: 10.1016/j.lungcan.2020.06.013. Epub 2020 Jun 17.
9
SARS-CoV-2 infection in an advanced rheumatoid arthritis patient.一名晚期类风湿性关节炎患者感染了新型冠状病毒。
APMIS. 2020 Dec;128(12):654-656. doi: 10.1111/apm.13080. Epub 2020 Oct 7.
10
Where are we with understanding of COVID-19?我们对新冠病毒的了解处于什么程度？
Adv Biol Regul. 2020 Dec;78:100738. doi: 10.1016/j.jbior.2020.100738. Epub 2020 Jun 20.
引用本文的文献
1
Effect of Chinese herbal medicine (CHM) as an adjunctive therapy in distinct stages of patients with COVID-19: A systematic review and meta-analysis.中药作为新型冠状病毒肺炎患者不同阶段辅助治疗的效果：一项系统评价与Meta分析
PLoS One. 2025 Feb 13;20(2):e0318892. doi: 10.1371/journal.pone.0318892. eCollection 2025.
2
Efficacy and Safety of Huashi Baidu Granules in Treating Patients with SARS-CoV-2 Omicron Variant: A Single-Center Retrospective Cohort Study.化湿败毒颗粒治疗新型冠状病毒奥密克戎变异株感染患者的有效性和安全性：一项单中心回顾性队列研究。
Chin J Integr Med. 2024 Feb;30(2):107-114. doi: 10.1007/s11655-023-3549-8. Epub 2023 May 24.
3
Chinese medicine for residual symptoms of COVID-19 recovered patients (long COVID)-A double-blind, randomized, and placebo-controlled clinical trial protocol.用于新冠康复患者（新冠后遗症）残余症状的中药——一项双盲、随机、安慰剂对照临床试验方案。
Front Med (Lausanne). 2023 Jan 4;9:990639. doi: 10.3389/fmed.2022.990639. eCollection 2022.
4
A Meta-Analysis of 13 Randomized Trials on Traditional Chinese Medicine as Adjunctive Therapy for COVID-19: Novel Insights into Lianhua Qingwen.一项针对 COVID-19 的中药辅助治疗的 13 项随机试验的荟萃分析：连花清瘟的新见解。
Biomed Res Int. 2022 Oct 30;2022:4133610. doi: 10.1155/2022/4133610. eCollection 2022.
5
Efficacy and Safety of Chinese Medicine Lianhua Qingwen for Treating COVID-19: An Updated meta-Analysis.中药连花清瘟治疗新型冠状病毒肺炎的疗效与安全性：一项更新的Meta分析
Front Pharmacol. 2022 Jun 3;13:888820. doi: 10.3389/fphar.2022.888820. eCollection 2022.
6
Frequently Used Allopathic and Traditional Medicine for COVID-19 Treatment and Feasibility of Their Integration. 常用于 COVID-19 治疗的对抗疗法和传统医学及其整合的可行性。
Chin J Integr Med. 2022 Nov;28(11):1040-1047. doi: 10.1007/s11655-021-3512-5. Epub 2022 May 4.
7
Clinical characteristics and impacts of traditional Chinese medicine treatment on the convalescents of COVID-19.新型冠状病毒肺炎恢复期患者的中医临床特征及治疗影响。
Int J Med Sci. 2021 Jan 1;18(3):646-651. doi: 10.7150/ijms.52664. eCollection 2021.
8
Herbal plants coordinate COVID-19 in multiple dimensions - An insight analysis for clinically applied remedies.草药植物在多维度协同 COVID-19——临床应用药物的深入分析。
Int J Med Sci. 2020 Oct 22;17(18):3125-3145. doi: 10.7150/ijms.50260. eCollection 2020.
9
Chinese Medicine, Which Targets Body's Response State, Is An Effective Way to Treat Epidemic Infectious Diseases.中医针对人体的反应状态，是治疗传染病的有效方法。
Chin J Integr Med. 2022 Feb;28(2):168-175. doi: 10.1007/s11655-020-3324-z. Epub 2020 Oct 10.
10
Combating COVID-19 with integrated traditional Chinese and Western medicine in China.中国中西医结合抗击新冠肺炎疫情。
Acta Pharm Sin B. 2020 Jul;10(7):1149-1162. doi: 10.1016/j.apsb.2020.06.009. Epub 2020 Jun 27.
本文引用的文献
1
Interpretation of the Traditional Chinese Medicine portion of the diagnosis and treatment protocol for corona virus disease 2019 (Trial Version 7).新型冠状病毒肺炎诊疗方案（试行第七版）中医部分解读。
J Tradit Chin Med. 2020 Jun;40(3):497-508. doi: 10.19852/j.cnki.jtcm.2020.03.019.
2
Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs.中医可否用于预防 2019 年冠状病毒病（COVID-19）？对历史经典、研究证据和当前预防方案的回顾。
Chin J Integr Med. 2020 Apr;26(4):243-250. doi: 10.1007/s11655-020-3192-6. Epub 2020 Feb 17.
3
[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].[RAS抑制剂可能是治疗新冠肺炎的良好选择]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16;43(0):E014. doi: 10.3760/cma.j.issn.1001-0939.2020.0014.
4
A novel coronavirus outbreak of global health concern.一场引发全球卫生关注的新型冠状病毒疫情。
Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24.
5
XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.血必净注射液对比安慰剂治疗重症社区获得性肺炎患者的随机对照试验。
Crit Care Med. 2019 Sep;47(9):e735-e743. doi: 10.1097/CCM.0000000000003842.
6
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.托珠单抗抑制白细胞介素-6受体对类风湿关节炎患者的影响（OPTION研究）：一项双盲、安慰剂对照的随机试验。
Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5.
Zotero 插件